It is interesting to note that doxorubicin and cisplatin, both of which, in U-2 OS osteosarcoma cells, result in NF-κB dependent repression of anti-apoptotic target genes through different mechanisms [7,8] are used in combination for the treatment of osteosarcoma in the clinic [13]. Here, NFKB1 is linked to osteosarcoma.